Bictegravir Associated With High Levels Of Virologic Suppression For Pregnant Patients With HIV, Study Finds

Infectious Disease Advisor (6/26, McSwiggin) reports, “The use of bictegravir in pregnant women with HIV infection is associated with high levels of virologic suppression and a favorable safety profile, according to study results published in Clinical Infectious Diseases.” In the study, “among patients who received bictegravir during pregnancy, the mean gestational age at treatment initiation was 24.7 weeks, most (91.5%) achieved a virologic load of fewer than 200 copies/mL by the time of delivery, and 9 patients had detectable viremia at the time of delivery, 2 of whom had been on bictegravir for fewer than 4 weeks.”